How group A Streptococcus circumvents host phagocyte defenses

Future Microbiology

Volumn 2, Issue 1, 2007, Pages 75-84

  Kwinn, Laura A ^a   Nizet, Victor ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Complement; Group A Streptococcus; Innate immunity; Macrophage; Neutrophil; Phagocytosis; Streptococcus pyogenes; Virulence factor

Indexed keywords

ANTIBODY; POLYPEPTIDE ANTIBIOTIC AGENT; REACTIVE OXYGEN METABOLITE;

APOPTOSIS; BACTERICIDAL ACTIVITY; BACTERIOLYSIS; CHEMOTAXIS; COMPLEMENT SYSTEM; DRUG TARGETING; GRAM POSITIVE BACTERIUM; HOST PATHOGEN INTERACTION; HOST RESISTANCE; HUMAN; INFECTION PREVENTION; INNATE IMMUNITY; MUCOSA; NONHUMAN; OPSONIZATION; PHAGOCYTE; PHAGOCYTOSIS; PRIORITY JOURNAL; REVIEW; STREPTOCOCCUS GROUP A; SYSTEMIC DISEASE;

GENE EXPRESSION REGULATION, BACTERIAL; HUMANS; MODELS, BIOLOGICAL; PHAGOCYTES; PHAGOCYTOSIS; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PYOGENES; VIRULENCE;

POSIBACTERIA; STREPTOCOCCUS PYOGENES; STREPTOCOCCUS SP. 'GROUP A';

EID: 34248670671     PISSN: 17460913     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460913.2.1.75     Document Type: Review

References (84)

1. Carapetis JR, Steer AC, Mulholland EK, Weber M: The global burden of group A streptococcal diseases. Lancet Infect. Dis. 5(11), 685-694 (2005).
2. Chatellier S, Ihendyane N, Kansal RG et al.: Genetic relatedness and superantigen expression in group A streptococcus serotype M1 isolates from patients with severe and nonsevere invasive diseases. Infect. Immun. 68(6), 3523-3534 (2000).
3. Kunkel SL, Standiford T, Kasahara K, Strieter RM: Interleukin-8 (IL-8): the major neutrophil chemotactic factor in the lung. Exp. Lung Res. 17(1), 17-23 (1991).
4. Middleton J, Neil S, Wintle J et al.: Transcytosis and surface presentation of IL-8 by venular endothelial cells. Cell 91(3), 385-395 (1997).
5. DiVietro JA, Smith MJ, Smith BR, Petruzzelli L, Larson RS, Lawrence MB: Immobilized IL-8 triggers progressive activation of neutrophils rolling in vitro on P-selectin and intercellular adhesion molecule- 1. J. Immunol. 167(7), 4017-4025 (2001).
6. Edwards RJ, Taylor GW, Ferguson M et al.: Specific C-terminal cleavage and inactivation of interleukin-8 by invasive disease isolates of Streptococcus pyogenes. J. Infect. Dis. 192(5), 783-790 (2005).
7. Hidalgo-Grass C, Mishalian I, Dan-Goor M et al.: A streptococcal protease that degrades CXC chemokines and impairs bacterial clearance from infected tissues. EMBO J. 25(19), 4628-4637 (2006).
8. + group A streptococci are phagocytized and killed in whole blood by C5a-activated polymorphonuclear leukocytes. Infect. Immun. 70(1), 350-359 (2002).
9. Cleary PP, Prahbu U, Dale JB, Wexler DE, Handley J: Streptococcal C5a peptidase is a highly specific endopeptidase. Infect. Immun. 60(12), 5219-5223 (1992).
10. Terao Y, Yamaguchi M, Hamada S, Kawabata S: Multifunctional glyceraldehyde-3-phosphate dehydrogenase of Streptococcus pyogenes is essential for evasion from neutrophils. J. Biol. Chem. 281(20), 14215-14223 (2006).
11. Brinkmann V, Reichard U, Goosmann C et al.: Neutrophil extracellular traps kill bacteria. Science 303(5663), 1532-1535 (2004).
12. Sumby P, Barbian KD, Gardner DJ et al.: Extracellular deoxyribonuclease made by group A Streptococcus assists pathogenesis by enhancing evasion of the innate immune response. Proc. Natl Acad. Sci. USA 102(5), 1679-1684 (2005).
13. Aziz RK, Ismail SA, Park HW Kotb M: Post-proteomic identification of a novel phage-encoded streptodornase, Sdal, in invasive M1T1 Streptococcus pyogenes. Mol. Microbiol. 54(1), 184-197 (2004).
14. Buchanan JT, Simpson AJ, Aziz RK et al.: DNase expression allows the pathogen group A Streptococcus to escape killing in neutrophil extracellular traps. Curr. Biol. 16(4), 396-400 (2006).
15. Gigli I, Fujita T, Nussenzweig V: Modulation of the classical pathway C3 convertase by plasma proteins C4 binding protein and C3b inactivator. Proc. Natl Acad Sci. USA 76(12), 6596-6600 (1979).
16. Thern A, Stenberg L, Dahlback B, Lindahl G: Ig-binding surface proteins of Streptococcus pyogenes also bind human C4b-binding protein (C4BP), a regulatory component of the complement system. J. Immunol. 154(1), 375-386 (1995).
17. Morfeldt E, Berggard K, Persson J et al.: Isolated hypervariable regions derived from streptococcal M proteins specifically bind human C4b-binding protein: implications for antigenic variation. J. Immunol. 167 (7), 3870-3877 (2001).
18. Blom AM, Berggard K, Webb JH, Lindahl G, Villoutreix BO, Dablback B: Human C4b-binding protein has overlapping, but not identical, binding sites for C4b and streptococcal M proteins. J. Immunol. 164(10), 5328-5336 (2000).
19. Berggard K, Johnsson E, Morfeldt E, Persson J. Stalhammar-Carlemalm M, Lindahl G: Binding of human C4BP to the hypervariable region of M protein: a molecular mechanism of phagocytosis resistance in Streptococcus pyogenes. Mol. Microbiol. 42(2), 539-551 (2001).
20. Persson J, Beall B, Linse S, Lindahl G: Extreme sequence divergence but conserved ligand-binding specificity in Streptococcus pyogenes M protein. PLoS Pathog. 2(5), E47 (2006).
21. Zipfel PF, Hellwage J, Friese MA, Hegasy G, Jokiranta ST, Meri S: Factor H and disease: a complement regulator affects vital body functions. Mol Immunol. 36(4-5), 241-248 (1999).
22. Jacks-Weis J, Kim Y, Cleary PP: Restricted deposition of C3 an M+ group A streptococci: correlation with resistance to phagocytosis. J. Immunol. 128(4), 1897-1902 (1982).
23. Horstmann RD, Sievertsen HJ, Knobloch J, Fischetti VA: Antiphagocytic activity of streptococcal M protein: selective binding of complement control protein factor H. Proc. Natl Acad. Sci. USA 85(5), 1657-1661 (1988).
24. Johnsson E, Berggard K, Kotarsky H et al.: Role of the hypervariable region in streptococcal M proteins: binding of a human complement inhibitor. J. Immunol. 161(9), 4894-4901 (1998).
25. Perez-Caballero D, Alberti S, Vivanco F, Sanchez-Corral P, Rodriguez de Cordoba S: Assessment of the interaction of human complement regulatory proteins with group A Streptococcus. Identification of a high-affinity group A Streptococcus binding site in FHL-1. Eur. J. Immunol. 30(4), 1243-1253 (2000).
26. Kotarsky H, Gustafsson M, Svensson HG, Zipfel PF, Truedsson L, Sjobring U: Group A streptococcal phagocytosis resistance is independent of complement factor H and factor H-like protein 1 binding. Mol. Microbiol. 41(4), 817-826 (2001).
27. Perez-Casal J, Okada N, Caparon MG, Scott JR: Role of the conserved C-repeat region of the M protein of Streptococcus pyoqenes. Mol. Microbiol. 15 (5), 907-916 (1995).
28. Pandiripally V, Gregory E, Cue D: Acquisition of regulators of complement activation by Streptococcus pyogenes serotype M1. Infect. Immun. 70(11), 6206-6214 (2002).
29. Courtney HS, Hasty DL, Dale JB: Anti-phagocytic mechanisms of Streptococcus pyogenes. binding of fibrinogen to M-related protein. Mol. Microbial. 59(3), 936-947 (2006).
30. Sandin C, Carlsson F, Lindahl G: Binding of human plasma proteins to Streptococcus pyogenes M protein determines the location of opsonic and non-opsonic epitopes. Mol. Microbiol. 59(1), 20-30 (2006).
31. Akesson P, Sjoholm AG, Bjorck L: Protein SIC, a novel extracellular protein of Streptococcus pyrogens interfering with complement function. J. Biol. Chem. 271(2), 1081-1088 (1996).
32. Fernie-King BA, Seilly DI, Willers C, Wurzner R, Davies A, Lachmann PJ: Streptococcal inhibitor of complement (SIC) inhibits the membrane attack complex by preventing uptake of C567 onto cell membranes. Immunology 103(3), 390-398 (2001).
33. Medina E, Molinari G, Rohde M, Haase B, Chhatwal GS, Guzman CA: Fc-mediated nonspecific binding between fibronectin-binding protein I of Streptococcus pyrogens and human immunoglobulins. J. Immunol. 163(6), 3396-3402 (1999).
34. Stenberg L, O'Toole P, Lindahl G: Many group A streptococcal strains express two different immunoglobulin-binding proteins, encoded by closely linked genes: characterization of the proteins expressed by four strains of different M-type. Mol. Microbiol. 6(9), 1185-1194 (1992).
35. Burova LA, Schalen C: Antigenic diversity of IgA receptors in Streptococcus pyogenes. FEMS Immunol. Med. Microbiol. 7(1), 47-54 (1993).
36. Carlsson F, Berggard K, Stalhammar-Carlemalm M, Lindahl G: Evasion of phagocytosis through cooperation between two ligand-binding regions in Streptococcus pyogenes M protein. J. Exp. Med. 198(7), 1057-1068 (2003).
37. Berge A, Kihlberg BM, Sjoholm AG, Bjorck L: Streptococcal protein H forms soluble complement-activating complexes with IgG, but inhibits complement activation by IgG-coated targets. J. Biol. Chem. 272(33), 20774-20781 (1997).
38. Collin M, Olsen A: Effect of SpeB and EndoS from Streptococcus pyogenes on human immunoglobulins. Infect. Immun. 69(11), 7187-7189 (2001).
39. Eriksson A, Norgren M: Cleavage of antigen-bound immunoglobulin G by SpeB contributes to streptococcal persistence in opsonizing blood. Infect. Immun. 71(1), 211-217 (2003).
40. von Pawel-Rammingen U, Johansson BP, Bjorck L: IdeS, a novel streptococcal cysteine proteinase with unique specificity for immunoglobulin G. EMBO J. 21(7), 1607-1615 (2002).
41. Agniswamy J, Lei B, Musser JM, Sun PD: Insight of host immune evasion mediated by two variants of group a Streptococcus Mac protein. J. Biol. Chem. 279(50), 52789-52796 (2004).
42. Akesson P, Moritz L, Truedsson M, Christensson B, von Pawel-Rammingen U: IdeS, a highly specific immunoglobulin G (IgG)-cleaving enzyme from Streptococcus pyogenes, is inhibited by specific IgG antibodies generated during infection. Infect. Immun. 74(1), 497-503 (2006).
43. Lei B, DeLeo FR, Hoe NP et al.: Evasion of human innate and acquired immunity by a bacterial homolog of CD11b that inhibits opsonophagocytosis. Nat. Med. 7(12), 1298-1305 (2001).
44. Lei B, DeLeo FR, Reid SD et al.: Opsonophagocytosis-inhibiting mac protein of group a streptococcus: identification and characteristics of two genetic complexes. Infect. Immun. 70(12), 6880-6890 (2002).
45. Collin M, Svensson MD, Sjoholm AG, Jensenius JC, Sjobring U, Olsen A: EndoS and SpeB from Streptococcus pyogenes inhibit immunoglobulin-mediated opsonophagocytosis. Infect. Immun. 70(12), 6646-6651 (2002).
46. Moses AE, Wessels MR, Zalcman K et al.: Relative contributions of hyaluronic acid capsule and M protein to virulence in a mucold strain of the group A Streptococcus. Infect. Immun. 65(1), 64-71 (1997).
47. Spencer RC: Invasive streptococci. Eur. J. Clin. Microbiol. Infect. Dis. 14(Suppl. 1), S26-S32 (1995).
48. Dale JB, Washburn RG, Marques MB, Wessels MR: Hyaluronate capsule and surface M protein in resistance to opsonization of group A streptococci. Infect. Immun. 64(5), 1495-1501 (1996).
49. Dinkla K, Rohde M, Jansen WT, Carapetis JR, Chhatwal GS, Talay SR: Streptococcus pyogenes recruits collagen via surface-bound fibronectin: a novel colonization and immune evasion mechanism. Mol. Microbiol. 47(3), 861-869 (2003).
50. Lembke C, Podbielski A, Hidalgo-Grass C, Jonas L, Hanski E, Kreikemeyer B: Characterization of biofilm formation by clinically relevant serotypes of group A streptococci. Appl. Environ. Microbiol. 72(4), 2864-2875 (2006).
51. Hoe NP, Ireland RM, DeLeo FR et al.: Insight into the molecular basis of pathogen abundance: group A Streptococcus inhibitor of complement inhibits bacterial adherence and internalization into human cells. Proc. Natl Acad. Sci. USA 99(11), 7646-7651 (2002).
52. Datta V, Myskowski SM, Kwinn LA et al.: Mutational analysis of the group A streptococcal operon encoding streptolysin S and its virulence role in invasive infection. Mol. Microbiol. 56(3), 681-695 (2005).
53. Miyoshi-Akiyama T, Takamatsu D, Koyanagi M, Zhao J, Imanishi K, Uchiyama T: Cytocidal effect of Streptococcus pyogenes on mouse neutrophils in vivo and the critical role of streptolysin S. J. Infect. Dis. 192(1), 107-116 (2005).
54. Andersen BR, Duncan JL: Activation of human neutrophil metabolism by streptolysin O. J. Infect. Dis. 141(5), 680-685 (1980).
55. Sierig G, Cywes C, Wessels MR, Ashbaugh CD: Cytotoxic effects of streptolysin a and streptolysin s enhance the virulence of poorly encapsulated group a streptococci. Infect. Immun. 71(1), 446-455 (2003).
56. Limbago B, Penumalli V, Weinrick B, Scott JR: Role of streptolysin O in a mouse model of invasive group A streptococcal disease. Infect. Immun. 68(11), 6384-6390 (2000).
57. Fontaine MC, Lee JJ, Kehoe MA: Combined contributions of streptolysin O and streptolysin S to virulence of serotype M5 Streptococcus pyogenes strain Manfredo. Infect. Immun. 71(7), 3857-3865 (2003).
58. Hakansson A, Bentley CC, Shakhnovic EA, Wessels MR: Cytolysin-dependent evasion of lysosomal killing. Proc. Natl Acad. Sci. USA 102(14), 5192-5197 (2005).
59. Madden JC, Ruiz N, Caparon M: Cytolysin-mediated translocation (CMT): a functional equivalent of type III secretion in Gram-positive bacteria. Cell 104(1), 143-152 (2001).
60. Michos A, Gryllos I, Hakansson A, Srivastava A, Kokkotou E, Wessels MR: Enhancement of streptolysin O activity and intrinsic cytotoxic effects of the group A streptococcal toxin, NAD-glycohydrolase. J. Biol. Chem. 281(12), 8216-8223 (2006).
61. Herwald H, Cramer H, Morgelin M et al.: M protein, a classical bacterial virulence determinant, forms complexes with fibrinogen that induce vascular leakage. Cell 116(3), 367-379 (2004).
62. Kobayashi SD, Braughton KR, Whitney AR et al.: Bacterial pathogens modulate an apoptosis differentiation program in human neutrophils. Proc. Natl Acad. Sci. USA 100(19), 10948-10953 (2003).
63. Tsai PJ, Lin YS, Kuo CF, Lei HY, Wu JJ: Group A Streptococcus induces apoptosis in human epithelial cells. Infect. Immun. 67(9), 4334-4339 (1999).
64. Nakagawa I, Nakata M, Kawabata S, Hamada S: Transcriptome analysis and gene expression profiles of early apoptosis-related genes in Streptococcus pyogenes-infected epithelial cells. Cell Microbiol. 6(10), 939-952 (2004).
65. Tamura F, Nakagawa R, Akuta T et al.: Proapoptotic effect of proteolytic activation of matrix metalloproteinases by Streptococcus pyogenes thiol proteinase (Streptococcus pyrogenic exotoxin B). Infect. Immun. 72(8), 4836-4847 (2004).
66. Ganz T: Fatal attraction evaded. How pathogenic bacteria resist cationic polypeptides. J. Exp. Med. 193(9), F31-F34 (2001).
67. Medina E, Rohde M, Chhatwal GS: Intracellular survival of Streptococcus pyogenes in polymorphonuclear cells results in increased bacterial virulence. Infect. Immun. 71(9), 5376-5380 (2003).
68. Medina E, Goldmann O, Toppel AW, Chhatwal GS: Survival of Streptococcus pyogenes within host phagocytic cells: a pathogenic mechanism for persistence and systemic invasion. J. Infect. Dis. 187(4), 597-603 (2003).
69. Bauer S, Tapper H: Membrane retrieval in neutrophils during phagocytosis: inhibition by M protein-expressing S. pyogenes bacteria. J. Leukoc. Biol. 76(6), 1142-1150 (2004).
70. Staali L, Bauer S, Morgelin M, Bjorck L, Tapper H: Streptococcus pyogenes bacteria modulate membrane traffic in human neutrophils and selectively inhibit azurophilic granule fusion with phagosomes. Cell Microbiol. 8(4), 690-703 (2006).
71. Brenot A, King KY, Janowiak B, Griffith O, Caparon MG: Contribution of glutathione peroxidase to the virulence of Streptococcus pyogenes. Infect. Immun. 72(1), 408-413 (2004).
72. Nizet V, Ohtake T, Lauth X et al.: Innate antimicrobial peptide protects the skin from invasive bacterial infection. Nature 414(6862), 454-457 (2001).
73. Kristian SA, Datta V, Weidenmaier C et al.: D-alanylation of teichoic acids promotes group a streptococcus antimicrobial peptide resistance, neutrophil survival, and epithelial cell invasion. J. Bacteriol. 187(19), 6719-6725 (2005).
74. Frick IM, Akesson P, Rasmussen M, Schmidtchen A, Bjorck L: SIC, a secreted protein of Streptococcus pyogenes that inactivates antibacterial peptides. J. Biol. Chem. 278(19), 16561-16566 (2003).
75. Nyberg P, Rasmussen M, Bjorck L: α2-Macroglobulin-proteinase complexes protect Streptococcus pyogenes from killing by the antimicrobial peptide LL-37. J. Biol. Chem. 279(51), 52820-52823 (2004).
76. McIver KS, Scott JR: Role of mga in growth phase regulation of virulence genes of the group A Streptococcus. J. Bacteriol. 179(16), 5178-5187 (1997).
77. Voyich JM, Sturdevant DE, Braughton, KR et al.: Genome-wide protective response used by group A Streptococcus to evade destruction by human polymorphonuclear leukocytes. Proc. Natl Acad. Sci. USA 100(4), 1996-2001 (2003).
78. Voyich JM, Braughton KR, Sturdevant DE et al.: Engagement of the pathogen survival response used by group A Streptococcus to avert destruction by innate host defense. J. Immunol. 173(2), 1194-1201 (2004).
79. Heath A, DiRita VJ, Barg NL, Engleberg NC: A two-component regulatory system, CsrR-CsrS, represses expression of three Streptococcus pyogenes virulence factors, hyaluronic acid capsule, streptolysin S, and pyrogenic exotoxin B. Infect. Immun. 67(10), 5298-5305 (1999).
80. Dalton TL, Scott JR: CovS inactivates CovR and is required for growth under conditions of general stress in Streptococcus pyogenes. J. Bacteriol. 186(12), 3928-3937 (2004).
81. Sumby P, Whitney AR, Graviss EA, DeLeo FR, Musser JM: Genome-wide analysis of group a streptococci reveals a mutation that modulates global phenotype and disease specificity. PLoS Pathog. 2(1), e5 (2006).
82. Cole JN, McArthur JD, McKay FC et al.: Trigger for group A streptococcal M1T1 invasive disease. FASEB J. 20(10), 1745-1747 (2006).
83. Graham MR, Virtaneva K, Porcella SF et al.: Analysis of the transcriptome of group A Streptococcus in mouse soft tissue infection. Am. J. Pathol. 169(3), 927-942 (2006).
84. Kreikemeyer B, Boyle MD, Buttaro BA, Heinemann M, Podbielski A: Group A streptococcal growth phase-associated virulence factor regulation by a novel operon (Fas) with homologies to two-component-type regulators requires a small RNA molecule. Mol. Microbiol. 39(2), 392-406 (2001).